Julia Schulz

Leipzig, SN, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission.

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission.

Journal: Blood advances
Published: January 26, 2022

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Journal: Cancers
Published: October 25, 2021

Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.

Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.

Journal: American journal of hematology
Published: June 13, 2021

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.

Journal: Bone marrow transplantation
Published: April 21, 2021

Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.

Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.

Journal: American journal of hematology
Published: March 23, 2021

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation.

Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation.

Journal: Blood cancer journal
Published: February 16, 2021

High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population.

High expression of the stem cell marker GPR56 at diagnosis identifies acute myeloid leukemia patients at higher relapse risk after allogeneic stem cell transplantation in context with the CD34+/CD38- population.

Journal: Haematologica
Published: October 15, 2020

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.

ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation.

Journal: Bone marrow transplantation
Published: August 24, 2020

Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.

Allogeneic stem cell transplantation mitigates the adverse prognostic impact of high diagnostic BAALC and MN1 expression in AML.

Journal: Annals of hematology
Published: July 06, 2020

Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation.

Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation.

Journal: Blood advances
Published: March 19, 2020

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation.

Outcomes of Older Patients with NPM1 Mutated and FLT3-ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation.

Journal: HemaSphere
Published: October 20, 2019

Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia.

Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia.

Journal: HemaSphere
Published: September 06, 2018
Showing 1-12 of 15

Last Updated: 09/26/2026